Trieste, 27 May 2024 - Ulisse Biomed SpA, an Italian healthcare biotech company active in the fields of diagnostics, theranostics and therapeutics, and Elettrobiochimica Srl, a company active in the field of laboratory diagnostics for the study, realisation and supply of analytical laboratories aimed at clinical pathology, microbiology, virology, genetics and oncological diagnosis, have signed a service agreement to support the development of an in vitro diagnostic medical device (IVDR).
The agreement provides for UBM to carry out analytical performance evaluation and production activities for an IVDR electrobiochemistry device, which it will then take to clinical validation.
The activities under the Agreement will be carried out at the R&D and production facility of Hyris, a wholly-owned subsidiary of UBM after the reverse takeover announced last December 2023.
The Agreement is in addition to the one already signed in January 2024 for the same services for another in vitro diagnostic medical device (IVDR).
"This further agreement between Elettrobiochimica and UBM confirms the strategic direction of this partnership, which began at the beginning of this year and is continuing fruitfully," says Stefano Occhiodoro, Owner and Managing Director of Elettrobiochimica. "Our team and UBM's team have already shown strong synergies and we are convinced that we will benefit tangibly from this collaboration," adds Occhiodoro.
"We are honoured to be able to support Elettrobiochimica in the development, validation and production of their IVDR products. Elettrobiochimica is a leading Italian company with more than 50 years of experience in the commercialisation of in-vitro diagnostic devices. Being able to contribute to their project consolidates their confidence in our platform services and solutions,' says Nicola Basile, CEO of Ulisse Biomed SpA. "The services of this agreement will be provided in Hyris' R&D and manufacturing facility, demonstrating how the integration of Hyris into the UBM Group strengthens our strategic positioning and enables mutual value generation," Basile concludes.
This deal was facilitated by BBA - Bespoke Biotech Advisory, a life sciences strategic advisory boutique.
